Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchNot Yet RecruitingNCT07185477
What this trial is testing

A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 20
Not applicableLooking for participantsNCT07309497
What this trial is testing

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich 208
Testing effectiveness (Phase 2)Looking for participantsNCT07158918
What this trial is testing

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
ABL Bio, Inc. 65
Testing effectiveness (Phase 2)Study completedNCT07102706
What this trial is testing

Phase I Trial of GR1803 Injection in Patients With RRMM

Who this might be right for
Multiple Myeloma (MM)
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 76
Testing effectiveness (Phase 2)Looking for participantsNCT04634552
What this trial is testing

Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 510
Testing effectiveness (Phase 2)Looking for participantsNCT07455734
What this trial is testing

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor Cancer
BioNTech SE 533
Early research (Phase 1)Active Not RecruitingNCT04137536
What this trial is testing

Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerAdvanced Pancreatic CancerPancreatic Adenocarcinoma+1 more
Memorial Sloan Kettering Cancer Center 7
Early research (Phase 1)Active Not RecruitingNCT04077463
What this trial is testing

Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 701
Testing effectiveness (Phase 2)Active Not RecruitingNCT06944470
What this trial is testing

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 78
Testing effectiveness (Phase 2)UnknownNCT04923048
What this trial is testing

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Who this might be right for
B Cell NHLCLL
Genor Biopharma Co., Ltd. 460
Testing effectiveness (Phase 2)Looking for participantsNCT06925724
What this trial is testing

Ivonescimab in People With Endometrial and Cervical Cancers

Who this might be right for
Endometrial CancerCervical Cancer
Memorial Sloan Kettering Cancer Center 50
Testing effectiveness (Phase 2)WithdrawnNCT07328490
What this trial is testing

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Who this might be right for
Extensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaSmall Cell Carcinoma
National Cancer Institute (NCI)
Not applicableNo Longer AvailableNCT04453397
What this trial is testing

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
TeneoOne Inc.
Early research (Phase 1)UnknownNCT00895323
What this trial is testing

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

Who this might be right for
Colorectal Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology 9
Early research (Phase 1)Study completedNCT04773522
What this trial is testing

JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 15
Early research (Phase 1)Looking for participantsNCT07667842
What this trial is testing

Study of D3L-002 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
D3 Bio (Wuxi) Co., Ltd 24
Post-approval studies (Phase 4)Looking for participantsNCT06057402
What this trial is testing

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Pfizer 80
Testing effectiveness (Phase 2)Looking for participantsNCT05543330
What this trial is testing

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Who this might be right for
Malignant Pleural EffusionsNSCLC Stage IV
Wuhan YZY Biopharma Co., Ltd. 116
Testing effectiveness (Phase 2)UnknownNCT02173093
What this trial is testing

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Who this might be right for
Disseminated NeuroblastomaRecurrent Neuroblastoma
University of Virginia 40
Testing effectiveness (Phase 2)Looking for participantsNCT07690787
What this trial is testing

JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

Who this might be right for
Recurrent/ Metastatic NPC
Chinese University of Hong Kong 49
Next Page